Phosphatase pioneer Positioned as the first mover in systematically drugging phosphatases with allosteric modulators, offering a unique value proposition to pharma partners seeking novel oncology targets.

Strategic partnerships backed by blue-chip investors and pursuing platform collaborations to build a robust pipeline across multiple indications, presenting opportunities for co-development deals and milestone-based partnerships.

Clinical progression Recent leadership appointments strengthen translational and chemistry capabilities, signaling readiness to advance programs toward clinic partnerships, licensing discussions, and potential out-licensing opportunities.

Global footprint Operations and investor base spanning the Netherlands and Germany with a biopharma focus, suggesting collaboration opportunities with European CROs, academic alliances, and regional pharma co-development.

Financial runway Seed financing raised to support a proprietary discovery platform and pipeline progression, indicating potential for staged funding partnerships, research collaborations, or supply of early-access programs to industry players.